RxDoctor Payments DataLook up a doctor →

George Scott, MD

Neurology · Louisville, KYNPI 1386845378

Payments from drug & device makers

$16,608in general payments, 2019–2025

Across 881 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • UCB, Inc.$1K
  • Vanda Pharmaceuticals Inc.$635
  • Pfizer$633
  • Eisai Inc.$607
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$15,84395%
  • Education$7665%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)130$2,232
AstraZeneca(2 entities)42$1,403
UCB, Inc.50$1,123
Vanda Pharmaceuticals Inc.30$635
Pfizer54$633
Eisai Inc.34$607
Genentech USA, Inc.39$565
Lilly USA, LLC28$548
CSL Behring22$517
Catalyst Pharmaceuticals, Inc.23$513
Novartis28$500
Argenx US, Inc.24$472
Biogen29$429
Amgen22$412
Amneal Pharmaceuticals LLC24$363
MDD US Operations, LLC19$326
Banner Life Sciences, LLC18$317
Teva Pharmaceuticals USA, Inc.8$298
TG Therapeutics, Inc.18$296
Biohaven Pharmaceutical Holding Company Ltd.23$259
EMD Serono, Inc.10$252
Johnson & Johnson(2 entities)12$248
Neurelis, Inc.11$221
SK Life Science, Inc.9$219
Takeda Pharmaceuticals U.S.A., Inc.9$205
Alnylam Pharmaceuticals Inc.9$191
Sanofi8$189
Acadia Pharmaceuticals Inc9$163
Bristol Myers Squibb8$142
Neurocrine Biosciences, Inc.7$142
Kyowa Kirin, Inc.7$141
Sunovion Pharmaceuticals Inc.11$138
Biohaven Pharmaceuticals, Inc.15$137
Octapharma USA, Inc.5$132
Livanova USA, Inc.4$124
Jazz Pharmaceuticals Inc.5$120
Lundbeck LLC5$106
Azurity Pharmaceuticals, Inc.6$100
Impel Pharmaceuticals Inc.6$100
Grifols USA, LLC4$86
Avion Pharmaceuticals4$79
Abbott3$75
Springworks Therapeutics, Inc.3$71
Aprecia Pharmaceuticals, LLC4$63
ANI Pharmaceuticals, Inc.3$57
Supernus Pharmaceuticals, Inc.4$53
Boston Scientific2$48
Aucta Pharmaceuticals, Inc.6$46
Vertex2$46
Aquestive Therapeutics, Inc.2$38
Mallinckrodt Enterprises LLC2$37
Arbor Pharmaceuticals, Inc.2$37
Mallinckrodt Hospital Products Inc.1$36
Merz Pharmaceuticals, LLC1$36
Otsuka America Pharmaceutical, Inc.2$31
Sumitomo Pharma America, Inc.2$31
Impel Pharmaceuticals LLC2$31
Vertical Pharmaceuticals, LLC2$27
Monteris Medical Corporation1$24
Genentech, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,608 in reported general payments places this provider in the 75th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$114,391
Medicare patients
439
Services billed
5,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$268,052
RebifInterferon Beta-1a/Albumin13$158,787
BetaseronInterferon Beta-1b15$141,919
NuplazidPimavanserin Tartrate21$103,728
Nurtec OdtRimegepant Sulfate55$82,985
RytaryCarbidopa/Levodopa54$65,100
BriviactBrivaracetam24$57,178
AptiomEslicarbazepine Acetate36$45,368
Teriflunomide16$44,697
Lacosamide188$42,438
QuliptaAtogepant24$25,520
Emgality PenGalcanezumab-Gnlm30$22,758
GlatopaGlatiramer Acetate13$19,508
UbrelvyUbrogepant14$18,862
KeppraLevetiracetam13$18,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$517$268,05213 claims
EMD Serono, Inc.Rebif$252$158,78713 claims
Acadia Pharmaceuticals IncNuplazid$163$103,72821 claims
PfizerNurtec Odt, Dilantin$633$88,04876 claims
UCB, Inc.Briviact, Vimpat$1,123$74,31139 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$363$68,69492 claims
Sunovion Pharmaceuticals Inc.Aptiom$138$45,36836 claims
AbbVieQulipta, Ubrelvy$2,232$44,38238 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$53$8,73815 claims
AstraZenecaFarxiga$1,403$6,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →